Who are Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vyvgart, Wydase, Efgartigimod, Trastuzumab and Hyaluronidase-oysk.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pertuzumab-trastuzumab-and-hyaluronidase-zzxf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endoglycosidase [EPC].

marketed Endoglycosidase [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) — Genentech, Inc..

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf TARGET	Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf	Genentech, Inc.	marketed	Endoglycosidase [EPC]
Vyvgart	EFGARTIGIMOD ALFA	Argenx Bv	marketed	Endoglycosidase [EPC]	IgG receptor FcRn large subunit p51	2021-01-01
Wydase	HYALURONIDASE	Baxter	marketed	Endoglycosidase	hyaluronic acid	1950-01-01
Efgartigimod	Efgartigimod	M. Peter Marinkovich	marketed	Endoglycosidase [EPC]	FcRn
Trastuzumab and Hyaluronidase-oysk	Trastuzumab and Hyaluronidase-oysk	Adrienne G. Waks	marketed	Endoglycosidase [EPC]	HER2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endoglycosidase [EPC] class)

Adrienne G. Waks · 1 drug in this class
Argenx Bv · 1 drug in this class
Genentech, Inc. · 1 drug in this class
M. Peter Marinkovich · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf — Competitive Intelligence Brief. https://druglandscape.com/ci/pertuzumab-trastuzumab-and-hyaluronidase-zzxf. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab